BioCentury
ARTICLE | Clinical News

Inovio reports Phase I data for HIV vaccine Pennvax-GP

May 26, 2017 5:17 PM UTC

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said data from the Phase I HVTN 098 trial in 94 healthy, HIV-uninfected volunteers showed that HIV vaccine Pennvax-GP produced "amongst the highest overall levels" of cellular and antibody immune response rates ever reported in human trials.

Pennvax-GP is a DNA vaccine targeting HIV env A, env C, gag polyprotein and pol, with coverage against HIV clades A, B and C. Inovio is developing the vaccine in collaboration with NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccines Trials Network (HVTN). NIAID funded the trial...

BCIQ Company Profiles

Inovio Pharmaceuticals Inc.